A higher level of PDCD2 expression was associated with lower overall survival (OS) for adrenocortical carcinoma (ACC), GBMLGG, LIHC, and Sarcoma (SARC) (Fig. 2A), poor disease-specific survival (DSS) in ACC, GBMLGG, and UCEC (Fig. 2B), and poor progression-free interval (PFI) in ACC, GBMLGG, HNSC, LIHC, OV, and UCEC (Fig. 2C). Here, PDCD2 is linked to sarcoma.